perjeta（pertuzumab）

Perjeta是一种靶向HER2受体的药物，HER2受体是在许多正常细胞外部发现的蛋白质，并且在HER2阳性癌中的癌细胞外部有大量的蛋白质。Perjeta is designed specifically to prevent the HER2 receptor from pairing (or ‘dimerising’) with other HER receptors (EGFR/HER1, HER3 and HER4) on the surface of cells, a process that is believed to play a role in tumour growth and survival. Binding of Perjeta to HER2 may also signal the body’s immune system to destroy the cancer cells. The mechanisms of action of Perjeta and Herceptin (trastuzumab) are believed to complement each other, as both bind to the HER2 receptor, but to different locations. The combination of Perjeta and Herceptin is thought to provide a more comprehensive, dual blockade of HER signalling pathways, thus preventing tumour cell growth and survival.

在美国，欧洲和其他国家，佩杰塔（Perjeta）与赫赛汀（Herceptin）和化学疗法联合批准，用于对HER2阳性，局部晚期，炎症或早期乳腺癌的人进行新辅助治疗（术前）治疗。晚期HER2阳性乳腺癌的线治疗。Perjeta还在包括欧盟和美国在内的80多个国家 /地区批准，结合了赫赛汀和化学疗法（基于Perjeta的治疗方案），用于辅助（手术后）治疗HER2阳性早期乳腺癌患者高风险的患者复发。